MSL Leaders



	Search:

Diagnosis and Management of Primary Progressive Multiple Sclerosis

Presented by The Johns Hopkins University School of Medicine

Supported through an educational grant from Genentech, Inc., and Biogen Idec.

Release date: July 30, 2007
Expiration date: July 30, 2008
Estimated time to complete activity: 1 hour

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity

Responsibility Statement
The Johns Hopkins University School of Medicine takes responsibility for the content, quality and scientific integrity of this CME activity.

Primary progressive multiple sclerosis (PPMS) affects about 10% of patients with the disease. Clinical data suggests that PPMS is a spectrum of illness, ranging from relapsing-remitting, secondary progressive to primary progressive. Certain clinical features are somewhat more characteristic of PPMS, but it appears to also have quite a bit in common with the other subtypes of the disease. In this program, Drs. Peter Calabresi, Bruce Cree and Michael Racke discuss recent clinical studies, review diagnostic criteria, and describe their own experiences in the diagnosis and management of PPMS.

Intended Audience
This activity has been designed to meet the educational needs of neurologists and other health care professionals involved in the management of patients with multiple sclerosis. There are no prerequisites.

At the conclusion of this activity, participants should be able to:

Outline the presentation, diagnosis, progression and clinical course of primary progressive multiple sclerosis (PPMS)
Discuss the pathogenic mechanism of MS with particular emphasis on PPMS and how its histopathology, and therefore pathogenesis, may differ from the other types of MS
Review of existing therapies for MS, in particular the studies of therapy in PPMS
Outline any new and potential therapies for PPMS, including data on safety and efficacy from clinical trials

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Peter Calabresi, MD (Program Chair)
Johns Hopkins School of Medicine
Associate Professor of Neurology
Multiple Sclerosis Center
Grants: Genentech, Inc., Novartis, Teva Neuroscience & Serono, Inc.
Consultant & honorarium: Amgen Inc., Novartis, Serono, Inc., Teva Neuroscience, Vertex Pharmaceuticals Inc.

Bruce Anthony Campbell Cree, MD, PhD, MCR
Assistant Professor of Neurology
University of California San Francisco School of Medicine
has no relevant conflict of interest to disclose.

Dr. Michael Racke has received grants, research support, speaker bureau and/or honorarium for National Institute of Health, National MS Society, Berlex, Teva Neuroscience, Serono.

Off-Label Discussion
The following faculty members have disclosed that their presentation will reference unlabelled/unapproved use of drugs or products:
Dr. Bruce Anthony Campbell Cree
Rituximab

No other faculty member has indicated that their presentation will include information on off-label products.

Disclaimer
The opinions and recommendations expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Uses of the Johns Hopkins University School of Medicine names imply review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Click here to review the complete CME information.


	Search: